NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System lessened its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 11.4% during the 4th quarter, HoldingsChannel reports. The firm owned 173,980 shares of the medical research company’s stock after selling 22,438 shares during the period. New York State Teachers Retirement System’s holdings in NeoGenomics were worth $2,815,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Redwood Investments LLC acquired a new position in shares of NeoGenomics during the 4th quarter worth approximately $2,399,000. Silverberg Bernstein Capital Management LLC purchased a new position in shares of NeoGenomics during the 4th quarter worth $456,000. Legato Capital Management LLC acquired a new position in shares of NeoGenomics during the 4th quarter valued at about $401,000. Moody National Bank Trust Division grew its holdings in shares of NeoGenomics by 22.3% in the fourth quarter. Moody National Bank Trust Division now owns 34,390 shares of the medical research company’s stock valued at $556,000 after purchasing an additional 6,281 shares during the period. Finally, Walleye Capital LLC acquired a new stake in NeoGenomics during the third quarter worth about $331,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Wall Street Analysts Forecast Growth

NEO has been the subject of several analyst reports. BTIG Research dropped their price target on shares of NeoGenomics from $25.00 to $21.00 and set a “buy” rating for the company in a research note on Friday, December 29th. Piper Sandler raised their target price on NeoGenomics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. The Goldman Sachs Group upped their price target on NeoGenomics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. William Blair reissued an “outperform” rating on shares of NeoGenomics in a research report on Wednesday, February 21st. Finally, Needham & Company LLC upped their target price on shares of NeoGenomics from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.50.

Insiders Place Their Bets

In other news, General Counsel Alicia C. Olivo sold 2,587 shares of NeoGenomics stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $14.96, for a total transaction of $38,701.52. Following the completion of the sale, the general counsel now directly owns 34,866 shares of the company’s stock, valued at approximately $521,595.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.30% of the stock is owned by company insiders.

NeoGenomics Trading Down 2.4 %

Shares of NEO stock opened at $13.75 on Tuesday. NeoGenomics, Inc. has a fifty-two week low of $11.03 and a fifty-two week high of $21.22. The company has a 50 day moving average price of $15.17 and a 200 day moving average price of $15.84. The stock has a market capitalization of $1.76 billion, a P/E ratio of -19.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.57, a quick ratio of 5.95 and a current ratio of 6.20.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, February 20th. The medical research company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.05. NeoGenomics had a negative net margin of 14.87% and a negative return on equity of 4.13%. The company had revenue of $155.55 million during the quarter, compared to analysts’ expectations of $152.90 million. Equities research analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.